Journal
FRONTIERS IN CARDIOVASCULAR MEDICINE
Volume 9, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fcvm.2022.864600
Keywords
atherosclerosis; gut flora; flavin-containing monooxygenase-3; trimethylamine; trimethylamine N-oxide
Categories
Funding
- Jiaxing Public Welfare Projects [2022AD30058]
- Key Medicine Disciplines Co-construction Project of Jiaxing Municipal [2019-ss-xxgbx]
- Pioneer Innovation Team of Jiaxing Institute of Atherosclerotic Diseases
- Program of the First Hospital of Jiaxing [2021-YA-011]
- Jiaxing Key Laboratory of Arteriosclerotic Diseases [2020-dmzdsys]
Ask authors/readers for more resources
This article summarizes the important progress in the evaluation of TMAO and AS in recent years and highlights novel potential approaches for the prevention and treatment of AS.
Atherosclerosis (AS) is one of the most common cardiovascular diseases (CVDs), and there is currently no effective drug to reverse its pathogenesis. Trimethylamine N-oxide (TMAO) is a metabolite of the gut flora with the potential to act as a new risk factor for CVD. Many studies have shown that TMAO is involved in the occurrence and development of atherosclerotic diseases through various mechanisms; however, the targeted therapy for TMAO remains controversial. This article summarizes the vital progress made in relation to evaluations on TMAO and AS in recent years and highlights novel probable approaches for the prevention and treatment of AS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
